Sunny founded A2-Ai in January of 2023, a venture dedicated to technology-driven clinical pharmacology and pharmacometrics using modern efficiency tools and automation. Previously, she spent time at Sanofi-Aventis, Amgen, and Pfizer. She co-founded her previous business (Ann Arbor Pharmacometrics Group, “A2PG”) in 2007 after Pfizer’s departure from its site in Ann Arbor, Michigan. With A2PG, she worked on hundreds of regulatory submissions for clients throughout its highly successful 15 years of PK/PD consulting, until her company was acquired. As a unique leader who is well-versed in both scientific and business aspects of the drug industry, she frequently helps clients proactively find alternative development pathways.
Sunny received her PhD in PK/PD under the supervision of Dr. Veng-Pedersen at University of Iowa, and also completed her MS in statistics from University of Iowa. Her previous education was at Seoul National University in Pharmacy (BS) with an MS in pharmaceutical analytical chemistry. She is passionate about seeking creative and pragmatic solutions for preclinical and clinical drug development problems using quantitative tools and clinical pharmacology paradigm, which has led to numerous successful MIDD cases.